AAKP & Renal Physicians Association Ask Congress to Intervene in ESA Policy Decisions

August 27, 2016 David Scott The American Association of Kidney Patients (AAKP) and Renal Physicians Association (RPA) contacted members of Congress to express our mutual concerns regarding the impact of policy decisions made by the Food and Drug Administration (FDA) and the Centers for Medicare and Medicaid Services (CMS) Read More

Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies

August 27, 2016 David Scott Ms. Marilyn Tavenner Administrator Centers for Medicare and Medicaid Services Department of Health and Human Services Attention: CMS-1526-P P.O. Box 8010 Baltimore, Maryland 21244-8010 Dear Ms. Tavenner: The Alliance for Home Dialysis (Alliance) Read More

AAKP Testimony

July 28, 2016 David Scott Testimony Before The Subcommittee On Health Of The House Committee On Ways And Means Statement of Kris Robinson, Executive Director and CEO, American Association of Kidney Patients, Tampa, Florida Testimony Before the Subcommittee on Health of the House Committee on Ways and Means June 26, 2007 Mr. Read More

AAKP HealthLine

April 2, 2016 D B register for our UPCOMING webinar(S): Understanding the Impact of Secondary Hyperparathyroidism | July 31, 2025, 3:00 – 4:00 pm ET (REGISTER)AAKP Healthline Webinars Click a topic below for webinars on specific areas of interest or use the search fieldto search for something more specific. Healthline Webinar Search Results: Read More

AAKP Testifies Before MEDCAC Panel on ESA Use in Kidney Transplant

July 20, 2011 David Scott Tampa, FL; Thursday, January 20, 2011 – On Wednesday, January 19, 2011, the American Association of Kidney Patients (AAKP) testified before the Center for Medicare and Medicaid Services’(CMS) Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) on the impact of erythropoiesis stimulating agents (ESAs) Read More